CN104703592A - 治疗轻度和中度阿尔茨海默病的方法 - Google Patents

治疗轻度和中度阿尔茨海默病的方法 Download PDF

Info

Publication number
CN104703592A
CN104703592A CN201380051206.0A CN201380051206A CN104703592A CN 104703592 A CN104703592 A CN 104703592A CN 201380051206 A CN201380051206 A CN 201380051206A CN 104703592 A CN104703592 A CN 104703592A
Authority
CN
China
Prior art keywords
day
subject
phenoxy
hydrochloride
achei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380051206.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·奥兰迪
D·J·克拉克
I·M·格里梅斯
M·C·瓦尔卡西-洛佩兹
M·J·考斯图拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Priority to CN201910466681.3A priority Critical patent/CN110292638A/zh
Publication of CN104703592A publication Critical patent/CN104703592A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CN201380051206.0A 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法 Pending CN104703592A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910466681.3A CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910466681.3A Division CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN104703592A true CN104703592A (zh) 2015-06-10

Family

ID=49354960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380051206.0A Pending CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法
CN201910466681.3A Pending CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910466681.3A Pending CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Country Status (16)

Country Link
US (3) US9717710B2 (cg-RX-API-DMAC7.html)
EP (1) EP2903606A1 (cg-RX-API-DMAC7.html)
JP (2) JP6566868B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150064743A (cg-RX-API-DMAC7.html)
CN (2) CN104703592A (cg-RX-API-DMAC7.html)
AU (2) AU2013327450B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015007641A8 (cg-RX-API-DMAC7.html)
CA (1) CA2886785C (cg-RX-API-DMAC7.html)
EA (1) EA201590687A1 (cg-RX-API-DMAC7.html)
HK (1) HK1207004A1 (cg-RX-API-DMAC7.html)
IL (1) IL237730B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03734A (cg-RX-API-DMAC7.html)
MX (1) MX377733B (cg-RX-API-DMAC7.html)
NZ (2) NZ705813A (cg-RX-API-DMAC7.html)
SG (2) SG11201502210VA (cg-RX-API-DMAC7.html)
WO (1) WO2014055588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ES2170104T3 (es) 1993-10-01 2002-08-01 Merrell Pharma Inc Inhibidores de la produccion de proteinas de beta-amiloide.
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
EP1184370B1 (en) 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US5962535A (en) 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6274615B1 (en) 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのRAGEへの結合を阻害する方法及びその結果
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2440042C (en) 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
JP2006522128A (ja) 2003-04-03 2006-09-28 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体−5のモジュレーターとしての4環イミダゾール誘導体
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
SI1703902T1 (sl) 2004-01-05 2011-02-28 Merz Pharma Gmbh & Co Kgaa Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni
DE102004050176A1 (de) 2004-09-20 2006-03-23 Universität Duisburg-Essen Optoelektronisches Bauelement und Verfahren zum Steuern von Tunnelelektronenströmen durch Photonen
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ,インコーポレイテッド [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
BRPI1012697A2 (pt) 2009-04-27 2016-03-29 High Point Pharmaceuticals Llc derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
US20170326113A1 (en) 2017-11-16
CA2886785C (en) 2022-06-07
MX2015003732A (es) 2015-09-23
MX377733B (es) 2025-03-11
JP2015535850A (ja) 2015-12-17
BR112015007641A8 (pt) 2018-04-03
CA2886785A1 (en) 2014-04-10
JP6566868B2 (ja) 2019-08-28
AU2013327450B2 (en) 2018-07-12
IN2015DN03734A (cg-RX-API-DMAC7.html) 2015-09-18
JP6894940B2 (ja) 2021-06-30
EP2903606A1 (en) 2015-08-12
BR112015007641A2 (pt) 2017-07-04
US20140100218A1 (en) 2014-04-10
US20190142803A1 (en) 2019-05-16
WO2014055588A1 (en) 2014-04-10
JP2019163301A (ja) 2019-09-26
AU2018203434A1 (en) 2018-06-07
CN110292638A (zh) 2019-10-01
KR20150064743A (ko) 2015-06-11
NZ739521A (en) 2019-06-28
AU2013327450A1 (en) 2015-05-14
NZ705813A (en) 2018-02-23
IL237730B (en) 2018-10-31
EA201590687A1 (ru) 2015-09-30
US9717710B2 (en) 2017-08-01
HK1207004A1 (en) 2016-01-22
SG11201502210VA (en) 2015-04-29
SG10201702648YA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
JP2019163301A (ja) 軽度および中等度アルツハイマー病の処置
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
KR102486434B1 (ko) 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
EP2663304B1 (en) Combination therapy
AU2006226811B2 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
US8455468B2 (en) Methods for the treatment of a traumatic central nervous system injury
US9937182B2 (en) Therapeutic strategies for the treatment of preeclampsia
Ueki et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
Pringle et al. Severe bradycardia due to interaction of timolol eye drops and verapamil
JP2018138572A (ja) 疾患および障害を検出、治療、および予防するための組成物および方法
Walters et al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161
HK40009571A (zh) 治疗轻度和中度阿尔茨海默病的方法
US20250114363A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high serum uric acid level
Zaremba-Pechmann et al. Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e
CN105250268B (zh) 厄贝沙坦组合物及其在制备治疗急性肾损伤的药物中的应用
Clough et al. Effect of inflammatory mediators on the developing micro circulation of the rabbit ear chamber
WO2020169041A1 (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: North Carolina

Applicant after: vTv Therapeutics LLC

Address before: North Carolina

Applicant before: TRANSTECH PHARMA, Inc.

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: TRANSFORMATION TECHNOLOGY PHARMA, LLC TO: VTV THERAPEUTICS LLC

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: North Carolina

Applicant after: VTVX Holdings I LLC

Address before: North Carolina

Applicant before: VTV THERAPEUTICS LLC

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20151130

Address after: North Carolina

Applicant after: VTV THERAPEUTICS LLC

Address before: North Carolina

Applicant before: VTVX Holdings I LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207004

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150610

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1207004

Country of ref document: HK